|
[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Suppliers list
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:SOS1-IN-5 CAS:2716956-47-5 Package:1removed
|
[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- manufacturers
- SOS1-IN-5
-
- $2785.00
-
2026-05-11
- CAS:2716956-47-5
- Purity:
- Supply Ability: 10g
|
| | [1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Basic information |
| Product Name: | [1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- | | Synonyms: | SOS1-IN-5;[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- | | CAS: | 2716956-47-5 | | MF: | C26H31F3N4O5 | | MW: | 536.54 | | EINECS: | | | Product Categories: | | | Mol File: | 2716956-47-5.mol | ![[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Structure](CAS/20211123/GIF/2716956-47-5.gif) |
| | [1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Chemical Properties |
| Boiling point | 614.9±55.0 °C(Predicted) | | density | 1.273±0.06 g/cm3(Predicted) | | pka | 6.57±0.20(Predicted) |
| | [1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Usage And Synthesis |
| Uses | SOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4)[1]. | | References | [1] Xin Li, et al. Pyrimidobicyclic derivatives, their preparation method and their application in medicine. Patent WO2021203768A1. |
| | [1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Preparation Products And Raw materials |
|